CNS regenerative and neural cell therapy
Parkinson’s, epilepsy, spinal cord injury, ALS, Alzheimer’s disease, and adjacent CNS programs where cells are being tested as defined products.
- Neural cells
- CNS delivery
- Safety follow-up
What it covers
A focused weekly read on regenerative medicine
Each issue follows a narrow set of cell-therapy developments: CNS programs, iPSC and stem-cell replacement, and selected MSC/exosome trials with clear product and endpoint details.
iPSC and stem-cell replacement
Cell-replacement products, iPSC-derived systems, organoids, disease models, and manufacturing methods that shape the next generation of therapies.
- iPSC
- Organoids
- Cell replacement
MSC and exosome programs
Clinical records and papers where product identity, route, dose, and endpoints are concrete enough to follow over time.
- MSC
- Exosomes
- Potency logic
Latest long reads
Recent long reads
Some stories need more room than a weekly capsule. These posts slow down around the trial design, source material, and scientific context.
Trial readout
HEAL-CHF Puts iPSC Heart Repair Through a Randomized Human Test
The first randomized human test of injected iPSC-derived cardiomyocytes pairs early functional improvements with ventricular arrhythmias, immune recognition, and an unresolved graft-persistence question.
Read long post
Paper worth your time
Airway Basal Cells Rebuild a Working Ferret Epithelium in Culture
A ferret airway study follows donor basal cells from niche creation through engraftment, multilineage differentiation, CFTR current, and mucus transport before a living-animal test.
Read long postIssue archive
All CellXperience Weekly issues
Each issue collects the week's most relevant trial records, papers, regulatory updates, and company developments in one place.
CellXperience Weekly - August 23, 2026
This issue covers the first randomized iPSC-cardiomyocyte trial, a Parkinson dopamine-cell study, two new hUC-MSC trials, hESC-derived stromal-cell safety testing, vascularized iPSC cell sheets, and airway basal-cell replacement.
CellXperience Weekly - August 16, 2026
This issue covers Rincell-1 in a cochlear-implant trial, acute and chronic stroke cell-therapy records, retinal RPE replacement, pediatric cerebral palsy MSCs, MultiStem MASTERS-2, and ALS iPSC-drug repurposing.
CellXperience Weekly - August 9, 2026
This issue covers stroke-focused MSC and secretome trial records, Parkinson cell-replacement comparison, human spinal interneurons in a rat SCI model, ALS extracellular vesicles, FTD iPSC-microglia, and hPSC differentiation quality.
CellXperience Weekly - July 24, 2026
A catch-up issue covering Parkinson and Huntington cell-replacement programs, iPSC spinal cord injury follow-up, chronic stroke trial design, retinal cell therapy, neonatal HIE MSCs, and CNS MSC records.
CellXperience Weekly - June 11, 2026
This week: FTD exosomes, two acute-stroke MSC trial records, retinal cell-therapy follow-up, Parkinson dopaminergic progenitors, Crohn’s extracellular vesicles, and a GMP-grade spinal cord injury paper.
CellXperience Weekly - May 25, 2026
This issue covers five-year NSI-566 follow-up, an Alzheimer’s exosome trial record, a small NMOSD MSC study, retinal replacement-cell development, iPSC disease models, and MSC product logic.
Recent analysis
From the archive
Longer notes on regulatory milestones, model-system papers, and clinical programs that remain useful after the weekly news cycle moves on.
Rincell-1 Brings Cell Replacement Into a Cochlear-Implant Trial
Rincell-1 puts an otic neural progenitor-cell therapy into a first-in-human cochlear-implant trial, with safety, delivery, neural-health measurement, immunosuppression, and long follow-up all visible from the start.
What B2065 Has to Prove After MultiStem
B2065 enters acute ischemic stroke as a randomized placebo-controlled adipose-MSC trial, while the terminated MASTERS-2 record and TREASURE publication show why the field has to read stroke cell therapy carefully.
Why Parkinson Cell-Replacement Trials May Start Disagreeing With Each Other
A Cell Stem Cell perspective argues that variation across Parkinson dopamine-cell therapy trials, patients, and graft sites may become one of the field’s central problems to solve.
The Important Part of This Spinal Cord Study Is the Circuit It Tries to Rebuild
A Science Translational Medicine paper uses human iPSC-derived V2a spinal interneurons to test whether transplanted cells can form a functional relay in an injured rat cervical spinal cord circuit.
Parkinson Cell Replacement Is Becoming a Field, Not a Single Story
STEM-PD, Kenai RNDP-001, and BlueRock bemdaneprocel show Parkinson dopaminergic cell replacement moving from isolated studies into a field readers can compare.
A Four-Patient iPSC Spinal Cord Injury Trial Clears an Important First Test
A Nature Medicine Phase 1 study reports 2-4 years of follow-up after direct iPSC-derived neural stem/progenitor cell transplantation in subacute cervical spinal cord injury.
Chronic Stroke Cell Therapy Moves Toward the Trial Design It Needs
hNPC01 long-term follow-up and a new CC-101 Phase 2 record show chronic stroke neural cell therapy moving toward longer observation and stronger controls.
An Intranasal MSC-Exosome Trial Enters Frontotemporal Dementia
Ruijin Hospital’s FTD trial record puts intranasal umbilical-cord MSC-derived exosomes into a three-arm Phase 1/2 design with placebo, two dose levels, and a disease-relevant clinical scale.
Two Acute-Stroke MSC Trials Bring Placebo Control Into Focus
Two new acute ischemic stroke MSC trial records use randomized, masked, placebo-controlled designs, with different products, dose strategies, and endpoints.
A Five-Year Safety Read on Neural Stem Cells in Cervical Spinal Cord Injury
A three-patient, five-year follow-up after direct NSI-566 neural stem cell implantation in chronic cervical spinal cord injury.
Reading the CB-Exo-A600 Alzheimer's Exosome Trial Before Results Exist
A recruiting Phase 1/2 trial record for intranasal umbilical-cord MSC-derived exosomes in mild-to-moderate Alzheimer’s disease.
Japan's iPSC Parkinson's Approval Is Real Progress, With Evidence Still Early
Japan’s conditional approval and reimbursement path for Amchepry/raguneprocel marks a real step for iPSC-derived neural cell therapy.
The Strange Part of This Parkinson's Organoid Paper Is Outside the Neuron
A 2026 SNCA triplication midbrain organoid paper points to extracellular matrix remodeling before overt degeneration appears in the model.
Reading NouvNeu001's Phase IIa and RMAT Update Clearly
iRegene’s NouvNeu001 has a U.S. Phase 1/2 trial record, sponsor-announced RMAT, and first U.S. dosing language.
Rezanecel Is Moving Toward the Trial Epilepsy Cell Therapy Needs
Neurona’s rezanecel/NRTX-1001 has sponsor-reported open-label seizure-reduction data and a serious Phase 3 path.
How it works
How the weekly selection works
The goal is to make each item readable now and still useful later, when results, follow-up, or regulatory updates arrive.
- A short weekly selection instead of a high-volume news feed
- Longer articles when a study, trial, or regulatory event needs context
- Plain language around trial stage, approval status, and what has actually been reported
- Attention to product, route, endpoint, durability, safety, and clinical usefulness
Need direct help
Move from curated reading into a scoped consultation
Use the newsletter for periodic scientific context. Book a consultation when a laboratory, GMP-readiness, R&D, due-diligence, or literature-review question needs direct advisory work.